ImetelChat

Ryan, I'm sorry for your pain... mine at least ended at $2.30 ;) Geron is not "working on the MDS study". They are hiring people to supervise a clinical-trial subcontracting company sometime after the middle of 2019. Yes, the preclinical from 2016 is fascinating. So are the results of preclinicals i...

Janssen hasn't transferred the trials to GERN yet because GERN doesn't exist. They have to hire people even to supervise the new trial subcontractor. The process is going to take almost a year according to Scarlett's lackadaisical timeline. Scarlett says there won't be a Phase 3 trial until after mi...

This has been discussed on SA and YMB. Someone emailed CG Capital and they said that Janssen is still mentioned "because they still have responsibility for the trial".

So apparently Geron is going to leave the fake connection to Janssen up until Janssen sues them to take it off.

the up-front cost to JNJ for ARWR is trivial. They didn't drop imet because they didn't have the cash, they dropped it because they didn't see it working well enough.

I've always complained that the "drug-development system" is no such thing. And this is a great example.... TI drugs work, but between the patent system and the monotherapy FDA trial system, they may never get into use inside the US. Those who attacked me as a "basher" for years,...

Geron has been out of the picture since Scarlett closed the labs all those years ago. Sergei Gryzanov was "Geron"... Scarlett is an absentee, over-retirement-age, patent troll. The sooner JNJ buys GERN patents, the sooner the quest for other TI drugs can start... at least two classes of wh...

Piketty has been debunked by many serious researchers. He's just clickbait. If you want to worry about something (something that creates inequality), worry about those who get to print themselves money. It's the simple problem that has plagued all modern economies. Here's one of the dozens of Pikett...

Sand, "Anne" has been notifying us of imminent EMA approval for years now

...and maybe someday she'll be right. But right now we don't even know if Janssen has applied for anything.

I looked and I looked but I couldn't find the CD

...is JNJ actually going to sit on this until Sept 28th?

This "new" patent was filed as a provisional by Sergei back in 2011.

You can read several papers on these modified G TIs on the Shay web site.

There is also this possibility for Imet 2.0:

https://www.ncbi.nlm.nih.gov/pubmed/26479411

...and everyone has known about these possibilities for years... except, apparently, JNJ

Hoosier has presented a very good summary of the possible upside scenarios.

Of course that means he will now be struck down by an unexplainably improbable concentration of cosmic rays. Farewell, Hoosier.

RIP Fish. Too bad he never had access to imetelstat.

Uh, didn't we hear that "John" DIED a long time ago?

I don't think this patent will apply to any therapeutic use of imet. Real-world therapies will always be combinations, so the issue of resistance to imet will be avoided. This is a good thing for imet's possible clinical use, of course.... the patent aims to limit the applicable patient population b...

Thanks for doing the legwork there Fish.

I deserve no credit, this was turned up by a SA poster. As usual, the question why we didn't do this work in 2003-5.... but it's very encouraging to see that it works on tumor explants as well as in no-feeder-layer cell culture ( a nearly useless screening technique, Vitamin C is the perfect cancer ...

Websites without e-commerce capability cost $200-500. It's insane that they didn't hire an intern to keep the old one updated, and it's insane that they kept the old one so long.

There is some good discussion of this patent application on SA. Bottom line is it's nothing bad for GERN... and it was filed two years ago, it took the patent office that long to publish it. No wonder there's so much work for patent lawyers.

Yeah, asked him whether the presentation was archived anywhere. No answer, of course.

I messaged Sergei on LinkedIn, haven't heard back... he may not even look at Linkedin, don't think he has any problems finding jobs